These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7965271)

  • 1. Cell biology and genetics of angiotensin in cardiovascular disease.
    Dzau VJ
    J Hypertens Suppl; 1994 Jul; 12(4):S3-10. PubMed ID: 7965271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of protective effects of ACE inhibition on coronary artery disease.
    Dzau VJ
    Eur Heart J; 1998 Sep; 19 Suppl J():J2-6. PubMed ID: 9796834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The significance of converting enzyme inhibitor angiotensin I to angiotensin II in treatment of patients with coronary disease].
    Halawa B
    Pol Merkur Lekarski; 1998 Jan; 4(19):32-4. PubMed ID: 9553407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors].
    Tschudi MR; Noll G; Lüscher TP
    Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasculoprotective and cardioprotective mechanisms of angiotensin-converting enzyme inhibition: the homeostatic balance between angiotensin II and nitric oxide.
    Gibbons GH
    Clin Cardiol; 1997 Nov; 20(11 Suppl 2):II-18-25. PubMed ID: 9422848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme and vascular remodeling.
    Heeneman S; Sluimer JC; Daemen MJ
    Circ Res; 2007 Aug; 101(5):441-54. PubMed ID: 17761934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials.
    Bertrand ME
    Curr Med Res Opin; 2004 Oct; 20(10):1559-69. PubMed ID: 15462689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of vascular smooth-muscle cell growth by angiotensin II.
    Pratt RE
    Blood Press Suppl; 1996; 2():6-9. PubMed ID: 8913533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ACE inhibition on neurohormones.
    Remme WJ
    Eur Heart J; 1998 Sep; 19 Suppl J():J16-23. PubMed ID: 9796836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mineralocorticoids and cardiovascular diseases. Status of knowledge from experimental and clinical studies.
    Pasquale PD; Stefano GD; Paterna S
    Ital Heart J; 2000 Sep; 1(9):595-604. PubMed ID: 11130838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis.
    Katoh M; Egashira K; Mitsui T; Chishima S; Takeshita A; Narita H
    J Mol Cell Cardiol; 2000 Jan; 32(1):73-83. PubMed ID: 10652192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The sympathetic nervous system and ischaemic heart disease.
    Remme WJ
    Eur Heart J; 1998 Jun; 19 Suppl F():F62-71. PubMed ID: 9651738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Growth stimulating properties of angiotensin II on the heart: consequences for therapy of heart failure].
    Schunkert H; Holmer SR; Riegger G
    Z Kardiol; 1993; 82 Suppl 4():1-6. PubMed ID: 8147057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.
    Brugts JJ; Ferrari R; Simoons ML
    Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):345-60. PubMed ID: 19379059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factor-induced cardiovascular remodeling and the effects of angiotensin-converting enzyme inhibitors.
    Galderisi M; de Divitiis O
    J Cardiovasc Pharmacol; 2008 Jun; 51(6):523-31. PubMed ID: 18520954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving rationale for angiotensin-converting enzyme inhibition in chronic heart failure.
    Banerjee A; Talreja A; Sonnenblick EH; LeJemtel TH
    Mt Sinai J Med; 2003 Sep; 70(4):225-31. PubMed ID: 12968195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases.
    Kim S; Iwao H
    Pharmacol Rev; 2000 Mar; 52(1):11-34. PubMed ID: 10699153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.